NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND…
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
NEW YORK, August 06, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics…
Single dose of psilocybin for depression shows promising results in UK's first publicly funded randomized trial
The first randomized controlled trial in the U.K. has found that a single dose of psilocybin, the active compound found in "magic mushrooms," produced significant improvements in depression compared with a placebo. Th...
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
LONDON & NEW YORK, August 06, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today…
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
Alignment with FDA on CMC and device plans for Phase 3Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estatePhase 2a results…
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
LONDON & NEW YORK, August 06, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it…
The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science
An Emory study is recruiting 800 people who faced post-psychedelic challenges, to learn what recovery actually takes. The post The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science appeare...
The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis
This secondary analysis of two Phase II randomised trials (n=53) examined mystical-type experiences during MDMA-assisted therapy for chronic PTSD. MDMA sessions produced higher scores than active placebo, and positive...
Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial
This double-blind, randomised, placebo-controlled feasibility trial (n=60) tested a single 25 mg dose of psilocybin with psychological support for people with treatment-resistant major depression in an NHS setting. Ps...
Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the Problem With Prohibition
Broken glassware from Sasha Shulgin’s historic laboratory is being transformed into art. Megan Bowers and Mikayla Hellwich join Joe Moore to discuss the project, MDMA history, DanceSafe, drug checking, prohibition, an...
New psychedelic candidate may spare the gut while still healing the brain
Psychedelic drugs are best known for altering perception and producing vivid hallucinations, but scientists are increasingly interested in what else they might do. A growing body of research suggests that these mind-a...
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK, August 05, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today…
Explorers of the Weird and the Wild
An Introduction from Wyld of the Woodling
A Psychedelic Crime Novel Exploring What Nonfiction Can’t Reach
Lindsay Kent's psychedelic novel is an argument for fiction as a way of arriving at truth. [...] Read More... The post A Psychedelic Crime Novel Exploring What Nonfiction Can’t Reach appeared first on DoubleBlind Mag.
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
TEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage…